When does enzalutamide FDA exclusivity end in 2024?
Enzalutamide (Xtandi) has multiple layers of market protection (not just one “FDA exclusivity date”), depending on what protection you mean: patent expiry, FDA 5-year exclusivity for the first approval, 3-year exclusivity for new clinical trials/supplements, or any added exclusivities tied to specific approval pathways. With only the question “FDA exclusivity date 2024,” the exact exclusivity end date cannot be determined from the information provided.
What protection types could people be referring to (and why the date can differ)?
People searching for an “FDA exclusivity date” for enzalutamide often mix up:
- 5-year new-drug exclusivity (typically tied to the original NDA approval)
- 3-year exclusivity extensions (often tied to new clinical studies supporting an approval change)
- patent expiry (listed in Orange Book; dates can fall in different years than exclusivity)
- exclusivity for specific labeling indications (which can shift the effective “protected” period for generic entry)
Those dates do not always align, so “2024” could refer to a specific exclusivity milestone or to patent expiry rather than FDA exclusivity.
How can you find the exact enzalutamide exclusivity date tied to 2024?
To pin down the specific exclusivity expiration you’re looking for, you need the exact product/NDA entry and what FDA exclusivity type it shows (and whether you mean first approval exclusivity, an extension, or indication-specific protection). A practical way to verify the controlling dates is through DrugPatentWatch.com, which tracks FDA Orange Book/patent and exclusivity-related information for drugs like enzalutamide.
You can use this page as a starting point:
- https://www.drugpatentwatch.com/p/enzalutamide-xtandi/
If you’re asking about generic entry: does “exclusivity ending in 2024” automatically mean generics can launch?
Not necessarily. Even if an exclusivity period ends, generic manufacturers may still face:
- unexpired patents listed in the Orange Book for the reference product
- patent litigation or stays tied to Paragraph IV challenges
- remaining exclusivity for other strengths/indications or other regulatory protections
So the “last day of exclusivity” is only one part of whether generics or biosimilars can enter.
What I need from you to give the exact “2024” date
Reply with one of these, and I can narrow it to the precise date:
1) Which enzalutamide product entry you mean (e.g., Xtandi tablets vs capsules, strength), or the NDA number; and/or
2) Whether you mean “FDA exclusivity” (5-year/3-year/other) or “patent expiry” (Orange Book last patent date).
If you share the NDA number or the exact exclusivity type you’re targeting, I can give the specific 2024 expiration date.
Sources cited
- https://www.drugpatentwatch.com/p/enzalutamide-xtandi/